Finance

Beta
Lists
ZYDUSLIFE:NSE
Zydus Lifesciences Ltd
₹1,108.00
+0.88%
(+9.70) 1D
Jun 11, 3:30:00 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for ZYDUSLIFE...
Open
₹1,095.00
High
₹1,110.40
Low
₹1,091.20
Mkt. cap
1.11T
Avg. vol.
1.94M
Volume
728.34K
Dividend
0.09%
Quarterly dividend
₹0.25
Ex-dividend date
Jul 24, 2026
P/E ratio
24.65
52-wk high
₹1,119.80
52-wk low
₹835.50
EPS
₹44.96
No. of employees
28K
Open
₹1,095.00
High
₹1,110.40
Low
₹1,091.20
Mkt. cap
1.11T
Avg. vol.
1.94M
Volume
728.34K
Dividend
0.09%
Quarterly dividend
₹0.25
Ex-dividend date
Jul 24, 2026
P/E ratio
24.65
52-wk high
₹1,119.80
52-wk low
₹835.50
EPS
₹44.96
No. of employees
28K
Analyst outlook
Analyst Ratings
Based on 2 analysts giving stock ratings to ZYDUSLIFE in the past 3 months
Buy
Buy
1
Hold
1
Sell
0
12 month forecast
Based on 2 Wall Street analysts offering 12 month price targets for ZYDUSLIFE in the last 3 months.
Highest
Current ₹1,108.00
₹1,050.00 (-5.23%)
Average
₹1,050.00 (-5.23%)
Lowest
₹1,050.00 (-5.23%)
News stories
From sources across the web
Profile
Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, is an Indian multinational pharmaceutical company headquartered in Ahmedabad. Primarily engaged in the manufacturing of generic drugs, the company ranked 100th in the Fortune India 500 list in 2020. Wikipedia
About Zydus Lifesciences Ltd
CEO-
Employees27.9K
Founded1952
Headquarters-
SectorPharmaceutical industry
Websitezyduslife.com
Last report
May 19, 2026
Fiscal period
Q4 2026
EPS / Est. (INR)
₹15.84 / ₹9.30
+70.40%beat
Revenue / Est. (INR)
75.87B / 70.37B
+7.81%beat
Fiscal Q4 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
65.74B
61.23B
68.64B
75.87B
Cost of goods sold
17.90B
16.90B
18.36B
19.76B
Cost of revenue
17.90B
16.90B
18.36B
19.76B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.05B
10.34B
11.40B
12.39B
Operating expense
29.91B
31.33B
37.36B
42.10B
Total operating expenses
47.80B
48.23B
55.72B
61.86B
Operating income
17.93B
13.00B
12.92B
14.01B
Other non operating income
1.55B
1.09B
1.11B
1.34B
EBT including unusual items
19.55B
16.93B
14.11B
16.59B
EBT excluding unusual items
19.55B
17.27B
14.96B
20.57B
Income tax expense
4.34B
4.54B
3.88B
3.18B
Effective tax rate
22.20%
26.82%
27.52%
19.19%
Other operating expenses
17.48B
17.97B
22.36B
24.62B
Net income
14.67B
12.59B
10.42B
12.72B
Net profit margin
22.31%
20.55%
15.18%
16.77%
Earnings per share
14.58
12.76
10.96
15.84
Interest and investment income
-
-
-
-
Interest expense
-847.00M
-1.01B
-1.30B
-1.23B
Net interest expenses
-847.00M
-1.01B
-1.30B
-1.23B
Depreciation and amortization charges
2.38B
3.02B
3.60B
5.08B
EBITDA
20.11B
15.70B
15.10B
17.69B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer